AstraZeneca Plc Reports Positive Results Of Phase III THEMIS Trial For Brilinta     

  • Sep 02, 2019 BST
  • Team Kalkine
AstraZeneca plc (LSE: AZN), has reported positive result of the Phase III THEMIS trial, where its medicine Brilinta (ticagrelor) indicted along with aspirin reduced the comparative risk for the composite of cardiovascular death, stroke or even heart attack by ten per cent compared with aspirin taken alone. Brilinta, the oral, reversible, direct-acting P2Y12 receptor antagonist, along with aspirin, is recommended for stopping atherothrombotic events in adult patients with the acute coronary syndrome.

On 2nd September 2019, at the time of writing, GMT 08:03 AM, AZN shares were trading at GBX 7,391.00, up by 73.00 points or 1.00% against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK